NCT00868868

Unknown

Pedometer and Exercise Study in Prostate Cancer Patients Wit...

Groupe de recherche en Urologie de la Mauricie Source

Compare

Other study identifiers

Sponsor study identifier

DC-990-0340

Study Type

observational

Estimated enrollment

400

Locations

1 country

Sites

1

Timeline

Study Start

June 2008

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

September 2011

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

September 2011

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Brief Summary

A randomized clinical trial evaluating the use of a pedometer and brief exercise coaching in prostate cancer patients treated with androgen deprivation therapy. The investigators want to demonstrate if there are less side effects of hormonal therapy and better quality of life in patients who made regular exercise.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: unknown
Estimated enrollment: 400 participants
Study completion date: September 2011
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
June 2008
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
March 24, 2009
Actual (reported)
First Posted
March 25, 2009
Actual (reported)
Primary Completion
September 2011
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
September 2011
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated: March 25, 2009
Status Verified: March 2009
Last Update Submitted: March 24, 2009

Conditions

Prostate Cancer

Keywords

PedometerProstateCancerHormonotherapyExercise

Eligibility Criteria

Age18 Years+

Sexmale

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Male subjects aged 18 years or older with histological confirmed prostate cancer.

You may qualify if:

years of age or older
Histologically proven prostate cancer
Treatment plan is to administer long term ADT (androgen deprivation therapy).
Patient must currently be treated with ADT for at least 2 weeks before enrollment in trial, and for no more than 6 months. Patient treated with a maximum androgen blockade strategy, combining an anti-androgen agent with a LHRH analog agent are admissible to this protocol, but not patients treated only with an anti-androgen agent alone.
Written informed consent to participate in the trial.

Sponsors & Collaborators

Groupe de recherche en Urologie de la Mauricie
Otherlead

Study Sites (1)

Groupe de Recherche en Urologie de la Mauricie

Trois-Rivières, G9A 3V7, Canada

RECRUITING

Dr Alain Maillette, UrologistCONTACT819-373-4141 grum@cgocable.ca

Dr Alain Maillette, UrologistPRINCIPAL INVESTIGATOR

MeSH Terms

Conditions

Prostatic NeoplasmsNeoplasmsMotor Activity

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital DiseasesBehavior

Study Officials

Dr Alain Maillette, urologist
Groupe de recherche en Urologie de la Mauricie
PRINCIPAL INVESTIGATOR

Central Study Contacts

Dr Alain Maillette, urologist

CONTACT

819-373-4141 grum@cgocable.ca

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER

Study Record Dates

First Submitted

March 24, 2009

First Posted

March 25, 2009

Study Start

June 2008

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

September 2011

Estimated (date passed)

NCT00651326

Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer

Phase 3Terminated

NCT01056562

An Alternative to A Fixed Schedule In Management Of Prostate Cancer

Completed

NCT01230905

Study to Monitor the Effects of Androgen Suppression Treatment on the Heart

Phase 4Completed

NCT00741364

Vitamin D Effects on Prostate Pathology

Phase 2Unknown

NCT00553878

Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer

Phase 2/3Completed

NCT00499174

Observation or Radical Treatment in Patients With Prostate Cancer

Not ApplicableTerminated

You may not qualify if:

Known hypersensitivity to Zoladex, Casodex (if applicable), or any component of these product, or to other similar agents
Severe cardiac disease (New York Heart Association class III or greater)
Severe lung disease
Uncontrollable pain
Unstable bone lesion
Any co-morbidity restraining the patient's ability to walk alone or to modify his walking habits (eg Parkinson's disease, advanced multiple sclerosis, leg amputation, ...)
Any concomitant condition that would make it undesirable, in the physician's opinion, for the subject to participate in the trial or would jeopardize compliance with the protocol.
Any contraindication to undertake the 6-minutes walk test (unstable angina or myocardial infarction during the previous month, a resting heart rate of more than 180, systolic blood pressure of more than 180, and a diastolic pressure of more than 100). The patient must have his cardiovascular conditions stabilized and controlled before enrollment in the trial.
Unwillingness or incapacity to consent to trial participation.

Contact the study team to confirm eligibility.

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

September 2011

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated

March 25, 2009

Record last verified: 2009-03

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00868868
Data provider: ClinicalTrials.gov
Source updated: 2009-03-25
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:33:00 UTC

Locations

CA(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations